
==== Front
Curr Neuropharmacol
Curr Neuropharmacol
CN
Current Neuropharmacology
1570-159X
1875-6190
Bentham Science Publishers

37491857
CN-22-543
10.2174/1570159X21666230724101321
Medicine, Neurology, Pharmacology, Neuroscience
Interaction of Brain-derived Neurotrophic Factor, Exercise, and Fear Extinction: Implications for Post-traumatic Stress Disorder
Antolasic Emily J. 1
Jaehne Emily J. 1
van den Buuse Maarten 1*
1 School of Psychology and Public Health, La Trobe University, Melbourne, Australia
* Address correspondence to this author at the School of Psychology and Public Health, La Trobe University, Melbourne, Victoria 3086, Australia; Tel: +61394795257; E-mail: m.vandenbuuse@latrobe.edu.au
04 8 2023
2024
22 4 543556
19 10 2022
16 1 2023
23 2 2023
© 2024 The Author(s). Published by Bentham Science Publishers
2024
The Author(s)
https://creativecommons.org/licenses/by/4.0/ © 2024 The Author(s). Published by Bentham Science Publishers. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode.
Brain-Derived Neurotrophic Factor (BDNF) plays an important role in brain development, neural plasticity, and learning and memory. The Val66Met single-nucleotide polymorphism is a common genetic variant that results in deficient activity-dependent release of BDNF. This polymorphism and its impact on fear conditioning and extinction, as well as on symptoms of post-traumatic stress disorder (PTSD), have been of increasing research interest over the last two decades. More recently, it has been demonstrated that regular physical activity may ameliorate impairments in fear extinction and alleviate symptoms in individuals with PTSD via an action on BDNF levels and that there are differential responses to exercise between the Val66Met genotypes. This narrative literature review first describes the theoretical underpinnings of the development and persistence of intrusive and hypervigilance symptoms commonly seen in PTSD and their treatment. It then discusses recent literature on the involvement of BDNF and the Val66Met polymorphism in fear conditioning and extinction and its involvement in PTSD diagnosis and severity. Finally, it investigates research on the impact of physical activity on BDNF secretion, the differences between the Val66Met genotypes, and the effect on fear extinction learning and memory and symptoms of PTSD.

Keywords

Post-traumatic stress disorder
anxiety disorders
brain-derived neurotrophic factor
exercise
Val66Met
stress
==== Body
pmc1 INTRODUCTION

According to the World Mental Health survey, around 70% of the population has reported exposure to one or more traumatic events within their lifetime [1]. Although most individuals exposed to a traumatic event will recover, cross-national studies suggest that the lifetime prevalence of Post-Traumatic Stress Disorder (PTSD) is around 5% among trauma-exposed individuals and ranges from 0.5% to 14.5% across countries [1-4]. With respect to gender differences, the overall lifetime prevalence of PTSD is reported to be about 10-12% in women and 5-6% in men [5]. According to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), PTSD is characterised by the presence of intrusive recollections, hyperarousal and reactivity, persistent avoidance of stimuli, and negative alterations in cognition and mood following exposure to a traumatic event [6].

Various psychosocial and environmental risk factors have been shown to increase the risk of the development of PTSD, such as the severity of the trauma, younger age at the time of trauma exposure, lower socioeconomic status, lower level of education, negative coping strategies, and lack of social support [6]. Early molecular and twin studies have suggested that PTSD is moderately inheritable, although the specific genes implicated remain unclear [7, 8]. A more recent genome-wide association study (GWAS) in a large cohort of around 200,000 individuals concluded that genetic factors account for between 5 and 20% of the variability of PTSD risk, similar to the genetic component of other mental illnesses, such as major depression [9]. These factors could include genes involved in brain plasticity and resilience.

This narrative review will first briefly describe the theoretical underpinnings of the development and persistence of intrusive and hypervigilance symptoms commonly seen in PTSD, as these symptoms are the most well-researched within the literature and have been proposed to be mediated by neurobiological processes involved in learning and memory. It will then explore the current literature on the role of the neurotrophin, Brain-Derived Neurotropic Factor (BDNF), and its common single-nucleotide polymorphism, Val66Met, on fear extinction learning and memory in both human and animal models, including the relationship between this polymorphism and PTSD diagnosis and symptom severity. Finally, the feasibility of physical activity in treating impaired fear extinction and the potential role of increased BDNF expression will be analysed.

2 THEORIES AND STRUCTURES INVOLVED IN FEAR LEARNING AND MEMORY

The two-factor learning theory of fear and anxiety has been used to explain intrusive and hypervigilance symptoms seen in PTSD [10]. According to this theory, fear is acquired through classical conditioning processes and is maintained through operant conditioning through the negative reinforcement of avoidance behaviours [10]. Individuals with PTSD associate various stimuli present during the traumatic event with the memory of the event, causing these previously neutral stimuli to elicit fear and anxiety behaviors as conditioned responses [11]. In PTSD, these fear responses can become generalised to similar stimuli not present during the traumatic event, triggering flashbacks of the event and high levels of autonomic arousal. Individuals with PTSD will consequently avoid external and internal triggers to evade these feelings of anxiety and fear, which can include symptoms of panic. Exposure therapy utilises this theory to treat PTSD and other anxiety disorders by gradually exposing these individuals to stimuli associated with the traumatic event until they fail to elicit a fear response through extinction learning [11].

The Pavlovian classical conditioning paradigm has been utilised in animal models to study the acquisition and extinction of intrusive recollections and hyperreactivity symptoms of PTSD [12, 13]. This paradigm states that associative learning comprises the pairing of a neutral conditioned stimulus (CS) with an aversive unconditioned stimulus (US), which then elicits a conditioned fear response (CR) [14]. Fear extinction occurs when the CS is presented in the absence of the US, causing a gradual reduction in the magnitude and frequency of the CR [15]. However, in some individuals, the CR will reappear; for example, spontaneous recovery refers to the re-emergence of an extinguished CR after a period of extinction [16]. Renewal is when the CS is presented in a different context than the original CS-US pairing and elicits a CR. Reinstatement refers to the recovery of a CR after re-exposure to the US following extinction [14-16].

As could be expected, cerebral structures involved in contextual and cue-dependent fear regulation have also been implicated in PTSD, and it has been noted that the neural circuitry involved in fear and anxiety, also implicated in PTSD in humans, is highly conserved throughout evolution [12]. Brain regions involved include the hippocampus, a structure responsible for associative learning and pairing contextual information with memories, and the amygdala, which is responsible for storing fear memories and the expression of fear [17]. Two structures within the medial prefrontal cortex (mPFC), the dorsal anterior cingulate cortex (dACC), also known as the prelimbic cortex (PL) in rodents, and the ventromedial prefrontal cortex (vmPFC), also known as the infralimbic cortex (IL) in rodents, have been shown to have opposing influences on fear processing. The dACC is crucial for fear learning, while the vmPFC is required for fear extinction [17, 18].

In the brain, several neurotransmitter systems have been implicated in PTSD symptoms, notably norepinephrine, serotonin and glutamate, likely in conjunction with hypothalamic-pituitary-adrenal (HPA) axis dysfunction [19]. Not surprisingly, pharmacotherapy for PTSD may include drugs that target these systems, including selective serotonin reuptake inhibitors (SSRIs), selective serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants [20], and atypical antipsychotics, which target several of these neurotransmitters [19]. However, no single pharmacotherapy has been shown to be fully effective against PTSD symptoms, and only two are FDA-approved in the USA, the SSRIs sertraline and paroxetine. This may be caused by the condition showing substantial variability in symptom type and severity, as well as the possible role of genetic variants which influence the effectiveness of drug treatments [9]. This review will focus on one such source of genetic variability, neurotrophic adaptability in the brain, which has also been proposed as a target mediator of current pharmacotherapy, as well as alternative treatments, such as exercise.

3 BRAIN-DERIVED NEUROTROPHIC FACTOR

Neurotrophins comprise a family of proteins that play an essential role in synaptic function, plasticity and neuronal survival, and responses to stress within the mammalian nervous system [21, 22]. BDNF is a neurotrophin that is a prominent promoter of neuronal growth and plasticity in the brain throughout the lifespan [23]. The BDNF gene is located on chromosome 11p13-14 and comprises one main coding exon and multiple promotors to direct the site-specific transcription of the mature BDNF protein [24]. The BDNF protein is first synthesised as a 32 kDa precursor molecule called proBDNF, which itself can bind to the p75 receptor and the sortilin receptor complex to invoke apoptosis [25]. However, most proBDNF is cleaved intra- and extracellularly by plasmin, furin, and protein convertases into truncated or 14 kDa mature BDNF [24-26]. Until recently, the function of truncated BDNF was largely unknown but is now thought to be involved in altering neuronal physiology [27].

BDNF and its receptor, Tropomyosin-Related Kinase B (TrkB), are found within brain structures involved in learning and memory, such as the cortex, hypothalamus, hippocampus, and amygdala [28], each of which has also been implicated in anxiety disorders and PTSD. The binding of mature BDNF to TrkB triggers several signalling cascades that modulate synaptic transmission and plasticity [24, 29] and enhance neurogenesis and cell survival [30]. Such modulating effects of BDNF at the synapse have been deemed essential for molecular and electrophysiological processes required in long-term learning and memory [29-31], which could be involved in PTSD. Specifically, BDNF is secreted during the induction of long-term potentiation (LTP) and influences synaptic strength in a complex time- and brain region-dependent manner, as reviewed recently [32]. Enhanced LTP following TrkB activation, either by BDNF or other mechanisms, involves phospholipase Cγ and subsequently cyclic AMP-responsive element-binding protein (CREB) [29].

It should be noted that mice that are heterozygous for BDNF and consequently only have approximately half of the concentration of the neurotrophin in the brain [33] show intact spatial memory [34, 35], suggesting compensatory mechanisms to maintain optimal cellular signalling, for example, up-regulation of other neurotrophins, such as NT-4 [33]. In contrast, marked cognitive deficits have been described in reports on patients with BDNF heterozygosity [36] or mutations in the gene encoding for TrkB and NTRK2 [37, 38].

In terms of pharmacotherapy, there is reasonable consensus that SSRIs and other antidepressant drugs are associated with increases in BDNF levels in the periphery and brain [39, 40], providing a possible explanation for the beneficial role of the neurotrophin in anxiety disorders, such as PTSD. Of interest, more recent work has shown that both typical and fast-acting antidepressants also directly bind to TrkB [41], thereby facilitating its activation by BDNF. Either mechanism may be involved in the beneficial actions of SSRIs in PTSD.

4 BDNF AND FEAR CONDITIONING IN ANIMAL MODELS

Several animal studies have demonstrated the role of BDNF in consolidating fear memories and extinction. Rodents who received intracranial BDNF infusion showed differential responses based on the stage of the fear conditioning paradigm and the location into which BDNF was injected. With respect to the frontal cortex, infusion of BDNF in the IL, but not the PL, after fear conditioning resulted in fear extinction in rats in the short and long term [42, 43]. Rats that underwent a chronic fear conditioning paradigm showed increased BDNF expression in the prelimbic cortex compared to those who underwent fear extinction training [44]. Rosas-Vidal et al. [42] found no changes in BDNF expression in the IL and PL following extinction training, although expression was increased in the hippocampus. However, Kataoka et al. [43] found that BDNF was decreased in both the mPFC and hippocampus, and decreased TrkB phosphorylation was also seen in the vmPFC. Infusion of BDNF into the IL has also been shown to reduce conditioned fear for up to 48 hours, even in the absence of extinction training [45]. In this study, rats that demonstrated impaired fear extinction also showed reduced BDNF in hippocampal inputs to the IL [45]. Another study found higher BDNF expression in the mPFC and the amygdala and reduced expression in the IL and hippocampus following an inescapable foot shock paradigm [46].

With respect to the hippocampus, administration of recombinant BDNF into this brain region at retrieval has been shown to constrain fear memory extinction after prolonged memory recall [47]. Additionally, rats that received an intrahippocampal infusion of anti-BDNF antibodies immediately and six hours after fear extinction training exhibited impaired fear extinction memory [48]. Infusing these antibodies after extinction memory activation impeded the recovery of the avoidance response [48]. Chaaya et al. [49] demonstrated that contextual fear conditioning produced more microglia and cells expressing BDNF in the dentate gyrus than unpaired fear conditioning. These studies demonstrated the involvement of BDNF in brain structures involved in contextual learning and memory and its role in fear extinction learning, memory, and recovery.

Rodent models of deficient BDNF expression have similarly demonstrated impairments in fear extinction. Male BDNF heterozygous knock-out mice were found to have impaired fear extinction memory [50-52], and this deficit appeared to become more pronounced with age [50]. The deficits in fear extinction were accompanied by a reduction of BDNF in the hippocampus, amygdala, and PFC [52]. BDNF-e4 mutant mice demonstrated impaired extinction of fear compared to wild-type controls, with increased hippocampal activation and decreased hippocampal-mPFC activation early in the extinction training, as well as increased activation of the mPFC during extinction recall [53]. Additionally, selective neocortical BDNF knock-out mice demonstrated deficits in the consolidation of cued fear but not in the acquisition or expression of learned fear [54]. This deficit in cued fear consolidation was then rescued with TrkB agonists, indicating that BDNF-TrkB signalling plays an important role in this process [54] and that deficient BDNF signalling is associated with impaired cued fear consolidation and extinction. In addition to age, it is possible that cognitive deficits in BDNF heterozygosity are only seen in the presence of, or are exacerbated by, additional environmental factors, such as stress [34]. This would be in line with the well-accepted role of neurotrophins in general, and BDNF in particular, in neuroplasticity and resilience in response to environmental stress [22, 55].

To study this gene-environment interaction, we used BDNF heterozygous rats and tested them in a standard three-day fear acquisition/extinction protocol [56]. Chronic stress was simulated by administrating the animals with the glucocorticoid and corticosterone in the drinking water of test animals. BDNF heterozygous rats showed reduced fear acquisition, and corticosterone treatment enhanced this to the level of wild-type rats (Fig. 1A). Importantly, when the animals underwent a fear extinction phase where they were repeatedly exposed to the CS without the accompanying US, reduced tone-induced freezing was observed as expected in all rats, except BDNF heterozygous rats treated with corticosterone, in which the development of fear extinction was reduced (Fig. 1B) and which showed impaired fear extinction memory on the final day of the protocol (Fig. 1C) [56]. These results suggested that the role of BDNF in fear acquisition and extinction may be to increase vulnerability to external factors, including chronic stress.

Most of these studies only used male rodents; therefore, the results are not necessarily generalisable to both sexes. As females are more likely to develop PTSD and tend to have greater severity of symptoms [2-5], a sex-specific vulnerability is important to investigate. BDNF expression and effects of BDNF deficiency have been shown to be influenced by circulating sex steroid hormone levels [57]. Baker-Andresen et al. [58] found that female mice demonstrated deficits in the retention of fear extinction memory compared to male mice. They also found that naïve female mice exhibited more significant methylation and decreased BDNF exon IV mRNA levels than naïve males [58].

Although these studies support the involvement of BDNF in fear learning and memory and demonstrate the neural structures involved in these processes, they lack generalisation to human physiology. Some of the animal models show extreme genetic modifications that do not occur or are extremely rare naturally in humans [12, 36]. There are no imaging methods to study altered BDNF signalling in the human brain; therefore, clinical studies have largely relied on measurement of circulating levels of the neurotrophin.

5 SYSTEMIC BDNF AND PTSD

Human studies have demonstrated inconsistent evidence for the involvement of BDNF in PTSD. Aksu et al. [59] found that serum BDNF and proBDNF levels were significantly lower in individuals with a diagnosis of PTSD compared to controls but found no correlation with the severity of symptoms. Stratta et al. [60] found that patients who reported more PTSD symptoms had lower serum BDNF than patients who reported fewer symptoms and controls, suggesting some involvement of BDNF in the severity of symptoms in PTSD. Controversially, some studies have found an increase in serum BDNF levels in individuals with a diagnosis of PTSD in comparison to ‘healthy’ controls [61, 62]. Matsuoka et al. [62] also found a positive correlation between serum BDNF levels and the severity of symptoms over six months. However, other studies have not found any correlation among BDNF levels, PTSD diagnosis, and symptom severity. For example, Su et al. [63] found no significant differences in the rates of PTSD diagnosis in road traffic accident victims depending on their BDNF plasma levels 48 hours and six months after the accident. However, those without a diagnosis showed a trend where BDNF levels increased over time [63], suggesting BDNF is reactive to stress and secretion may increase over time as the initial impact of stressors lessens.

In addition to reduced serum levels of BDNF in PTSD, studies have identified altered epigenetic control of BDNF gene expression [64, 65]. For example, higher DNA methylation at four CpG sites of the BDNF gene promoter was found in veterans exposed to combat in the Vietnam war and with PTSD compared to those exposed to combat but without PTSD. High methylation levels at the BDNF promoter CpG site and high combat exposure were significantly associated with PTSD diagnosis [65].

Overall, it should be noted that some of the studies described here used relatively small sample sizes, lacked comparison to healthy controls, or gathered their samples from one institution; therefore, their results could be influenced by sample biases. Additionally, many of these studies are correlational, and there is little control over other psychosocial factors influencing the results; therefore, they cannot conclude that the results reflect only the influence of BDNF. It is also unclear whether changes in BDNF are a reaction to trauma or a premorbid vulnerability in these populations. As BDNF plays different roles in different brain regions, it is furthermore extremely difficult to reliably determine the direct relationship between BDNF levels and individual PTSD symptoms by measuring peripheral BDNF. PTSD is a complex disorder and likely has multiple psychobiological influences; therefore, it is possible that BDNF is not involved in all symptoms of PTSD.

The same problem arises when considering systemic BDNF-like treatments in a clinical setting. In humans, relatively little is known about interventions that impact BDNF signalling and may reduce PTSD symptoms. Some reports suggest that circulating levels of BDNF reflect changes in central levels; however, it is unclear if this applies to the transport of BDNF into the brain. Clearly, intra-cerebral injections are not feasible in humans, and systemically-injected BDNF is unlikely to reach relevant brain regions in effective concentrations unless, as yet, unapproved carrier mechanisms are employed [66]. Other strategies to increase BDNF signalling in the brain could include antidepressant drugs, some of which are known to increase BDNF expression [39, 40] or exercise.

Non-peptide TrkB receptor agonists are an alternative strategy to target central BDNF signalling [67], although this approach will still not be brain region-specific. Nevertheless, the pre-clinical and animal model literature shows promising results. Activation of TrkB by the flavone, 7,8-dihydroxy-flavone (7,8-DHF), reversed age-related deficits in contextual and cue-induced fear conditioning [68]. The authors suggested this effect of systemic administration of the flavone compound was mediated predominantly by an action in the amygdala [68]. A similar finding was reported by Andero et al. [69], who reported that 7,8-DHF enhanced both the acquisition of fear and its extinction, as well as rescued an extinction deficit caused by immobilization stress in mice [69]. Choi et al. [54] showed that the deficit in fear learning in mice with selective BDNF knockout in the prelimbic cortex could be reversed by systemic treatment with 7,8-DHF. Finally, specifically focusing on sex differences, impaired fear extinction in female mice compared to male mice could be rescued by systemic 7,8-DHF treatment [70]. Similar studies have not been done in humans, but the literature on animal models with 7,8-DHF supports the role of BDNF in fear conditioning and extinction and shows promise for the development of clinically-accepted drugs targeting BDNF signalling. Such an approach may need to take into account the effect of gene variants, particularly the BDNF Val66Met single-nucleotide polymorphism, which will be discussed in the next section.

6 BDNF VAL66MET POLYMORPHISM

Minor variants in a gene sequence can have a significant effect on gene expression and its regulation. A common genetic variation in the BDNF gene is the Val66Met polymorphism [23, 24]. This polymorphism involves a single-nucleotide substitution of guanine to adenine at position 196, resulting in an amino acid residue shift from valine (Val) to methionine (Met) within codon 66 of the BDNF prodomain [23, 24]. This means that the polymorphism does not result in an altered amino acid sequence of mature BDNF, which is the predominant form of BDNF in cellular signalling [71, 72]. Instead, the modification interferes with the binding of proBDNF to sortilin and consequently with intracellular trafficking, ultimately leading to reduced activity-dependent BDNF release [73, 74] and reduced BDNF-TrkB signalling [24]. Cultured hippocampal neurons have demonstrated an 18% decrease in BDNF secretion in neurons carrying one Met allele and a 29% decrease in neurons carrying two Met alleles [75, 76]. In human studies, the Met allele was associated with poorer episodic memory and abnormal hippocampal activation on fMRI [77]. In both human and rodent models, the Val/Val genotype represents a “wildtype,” while a Val/Met reflects heterozygosity and the Met/Met genotype homozygosity [27]. The Val66Met polymorphism is carried by 0.55% of Sub-Saharan Africans, 19.9% of Europeans, and 43.6% of Asians but is carried by up to 72% in certain populations [78]. Thus, unless specifically controlled for, studies on the role of BDNF in neurological functioning and psychiatric illness risk may produce different findings because of differential proportions of individuals with the Val/Val, Val/Met or Met/Met genotype depending on the ethnic distribution of participant populations [27, 78].

7 VAL66MET AND FEAR CONDITIONING IN ANIMAL MODELS

The research on the Val66Met polymorphism and fear extinction memory demonstrates a more explicit link between the involvement of BDNF in PTSD. The majority of the current literature suggests that the Met allele is associated with deficits in fear association learning or the persistence of fear memories over time when compared to the Val/Val genotype [79-83]. Dincheva et al. [79] found no differences between genotypes in Val66Met knock-in mice in contextual fear expression, but Met/Met mice did show a delayed expression of contextual fear over time. Giza et al. [81] highlighted this polymorphism's effect at a neuronal level, as they found ventral CA1 hippocampal neurons in Met/Met mice fail to adapt their activity during fear extinction training, resulting in deficits in the persistence of fear memories. Soliman et al. [83] found impaired fear conditioning in those with the Met allele compared to the Val/Val genotype in both human and animal models. Additionally, they found atypical frontoamygdala activity in humans with the Met allele [83]. This provides evidence for the involvement of this polymorphism in the neural processes involved in fear association learning [83]. Similarly, Mühlberger et al. [82] found that Met-carrying individuals demonstrated a generalisation of fear responses in novel contexts, suggesting deficits in fear association learning. Others found heightened amygdala responses and reduced subgenual anterior cingulate responses in Met allele carriers during fear conditioning [84]. They also found heightened responses in the insula, amygdala, and hippocampus during early extinction in Met allele carriers but no differences during late extinction [84].

In marked contrast, some studies have suggested a protective effect of the Met allele as demonstrated by superior fear extinction learning and reduced fear memory and spontaneous recovery [85-87]. Jaehne et al. [87] suggested that the impact of this polymorphism seems specific to fear memory as no genotype differences were seen in measures of anxiety-like behaviour, such as on the elevated plus maze, or other memory measures, such as novel-object recognition or short-term spatial memory in the Y-maze. However, perhaps this polymorphism alone does not produce deficits in fear learning, extinction learning, and memory and, as discussed above, may interact with stress to increase vulnerability [88]. Animal studies have demonstrated promising evidence of such a genotype and stress interaction effect, as shown by impaired fear extinction in Met/Met mice exposed to chronic corticosterone treatment [89, 90]. Notaras et al. [90] also found an increase in the expression of glucocorticoid receptors in the dorsal hippocampus in this genotype during adolescence. Raju et al. [89] found a sex-specific interaction effect whereby corticosterone treatment selectively abolished fear extinction in female Met/Met mice, which also showed decreased amygdala GABAergic interneuron expression.

Following earlier studies in BDNF heterozygous rats and Val66Met mice [56, 89, 90], we recently found no differences between Val/Val, Val/Met and Met/Met mice in terms of fear acquisition, contextual fear and cue-induced fear (Figs. 2A-C). Interestingly, these mice were the vehicle-treated controls in a study in which the effects of a chronic methamphetamine treatment paradigm were investigated, including daily intraperitoneal injections [91]. It is possible that even in the vehicle-treated control mice in this study, the added chronic stress of repeated injections diminished underlying genotype differences, similar to the more controlled stress simulation by corticosterone treatment in other studies [90]. Therefore, it is important in animal model studies to take into account additional factors, such as housing conditions and frequency of handling, which could explain some of the discrepancies between study results [12, 92]. Other factors of relevance in the animal model literature are species differences [92, 93], rat and mouse strain differences [94] and, as mentioned above, sex differences [5, 95].

8 VAL66MET AND PTSD

The Val66Met polymorphism has been associated with PTSD diagnosis and symptom severity, although there are some inconsistencies between findings. Studies have found that the Met allele is overrepresented in PTSD populations compared to the Val/Val genotype [96-101]. The Met allele has also been associated with higher PTSD symptom severity than the Val/Val genotype [80, 96, 102, 103]. In addition, Young et al. [98] found that PTSD Met allele carriers demonstrated greater physiological responses in no threat and ambiguous threat conditions in a fear-potentiated acoustic startle paradigm, suggesting deficits in cued fear association learning. Felmingham et al. [80] found that poor fear conditioning was associated with greater PTSD symptom severity in individuals carrying the Met allele. Felmingham et al. [104] found that individuals with the Met allele with a diagnosis of PTSD demonstrated poorer responses to exposure therapy compared to patients with the Val/Val genotype. Similarly, Lyoo et al. [105] found that in individuals with a diagnosis of PTSD, the Val/Val genotype was associated with better symptom recovery than Met allele carriers.

In contrast, Jin et al. [106] found that the Val/Val genotype was associated with higher levels of childhood trauma and greater severity of PTSD symptoms in the Korean population. Additionally, a significant interaction in cortical thickness of the left fusiform and transverse temporal gyri and symptom severity in the Val/Val genotype was found [106]. However, some studies have found no association between the Val66Met genotype, PTSD diagnosis, and symptom severity [107-112], although Bruenig et al. [109] showed a trend towards a potential protective effect in the Val/Val genotype. Van den Heuvel et al. [107] also found that plasma BDNF was correlated with the number of lifetime trauma exposures, demonstrating BDNF’s reactivity to traumatic stress.

It is important to note that the vast majority of previous research has been conducted on male US veterans or military personnel or lacks comparison to a ‘healthy’ community population. Therefore, it lacks generalisability and may be influenced by sample biases. Another limitation of this research is that it relied on self-report for indications of past trauma, which is known to be subject to reporter biases. Furthermore, with many of the studies being correlational, there is no control over extraneous variables that may be influencing the results. Therefore, it is difficult to determine a cause-and-effect relationship between this polymorphism and PTSD susceptibility. However, it is unlikely that this polymorphism would increase vulnerability to PTSD on its own, and it likely interacts with stress, trauma exposure, and other genetic variations to increase susceptibility. Many of the human studies did not control for the current level of stress, which could have had an impact on learning and memory, and/or were based on highly educated Caucasian populations, therefore lacking generalisability. Additionally, most human studies had small sample sizes and uneven distributions between the genotypes, which might have affected the validity of the results. Overall, given this large number of limitations and potentially confounding factors, it is not surprising that a meta-analysis failed to find a genetic association between BDNF Val66Met and PTSD [111].

9 BDNF AND PHYSICAL ACTIVITY

Physical activity has been shown to provide cognitive benefits and regulate mood by stimulating increased BDNF concentrations in various brain regions [113, 114] and improving synaptic plasticity and cognition [115]. Animal studies have indicated that exercise increases BDNF concentrations in brain regions responsible for learning, memory, and emotional processing (i.e., the hippocampus, prefrontal cortex and amygdala) [116-119]. For example, an animal study using an inhibitory avoidance paradigm found that moderate exercise alleviated impaired fear extinction while increasing hippocampal BDNF [120]. In rats, voluntary exercise has similarly been shown to increase BDNF mRNA production in the hippocampus and neocortex, indicating that exercise increases the secretion of BDNF through the upregulation of BDNF gene transcription [121]. The exercise-induced increase in BDNF expression in the brain was associated with enhanced neurogenesis, including proliferation and neural differentiation of neural stem cells [122, 123] and may play a central role in stress resilience and PTSD-like behavior [124]. Indeed, treatment with the neurogenesis enhancer, memantine, improved social avoidance behavior in a PTSD model in rats [125]. Conversely, treatment with the neurogenesis inhibitor, valganciclovir, prevented long-term recovery of anxiety-like behavior and acute stress-induced corticosterone responses following a single combined stress model in rats [126].

Human studies have also demonstrated exercise-induced increased BDNF levels and responses to fear extinction training or exposure therapy in individuals with PTSD [127, 128]. This suggests the efficacy of using physical activity in addition to exposure-like therapies for the treatment of symptoms of PTSD. Meta-analyses have found an increase in peripheral blood BDNF levels after exercise in human participants, which was shown to increase with session duration [113, 129]. Regular exercise also intensified the increase in BDNF after a session [129]. These studies also found that women showed less change in their BDNF levels after exercise compared to males, suggesting that women may be less reactive to exercise-induced changes in BDNF secretion [113, 129]. Studies have shown increases in BDNF following exercise in other clinical disorders as well, such as depression, anxiety, neurodegenerative disorders and epilepsy, and have demonstrated benefits in terms of mood and cognitive functioning [130-133].

Differences in body composition and muscle mass may likely account for sex-specific differences in BDNF secretion. Increases in BDNF mRNA and BDNF expression have been observed in rats in response to muscle contraction [113], thus demonstrating that BDNF may be produced in the muscle during exercise. Therefore, as males generally have higher muscle mass than females, this may account for the greater production of BDNF. In addition, smaller samples of females compared to male participants may have resulted in the lack of significant findings among female participants. Additionally, only a few human studies have been able to demonstrate whether BDNF can cross the blood-brain barrier [113]. Although animal studies have demonstrated good evidence in support of this, it is, therefore, difficult to determine whether increases in peripheral BDNF indicate an increase in BDNF in the human cerebral cortex.

10 VAL66MET AND PHYSICAL ACTIVITY

There may be different responses among Val66Met genotypes following exercise. We recently confirmed this finding in a cohort of Val68Met rats that were housed in running-wheel cages and which developed high levels of exercise [134]. Exercise rats showed significantly higher BDNF gene expression in the hippocampus and levels of BDNF protein in the ventral hippocampus compared to sedentary rats housed under standard conditions [134], although some genotype differences were found between male and female rats (Fig. 3). Specifically, the effect of exercise on BDNF protein levels was most pronounced in Val/Val and Met/Met male rats and in Val/Met female rats.

Clinically, some studies have indicated that those with the Met allele demonstrate significant improvements in BDNF levels post-exercise interventions compared to Val homozygotes [135, 136]. Other studies have demonstrated improved cognitive and mood outcomes in response to physical activity in Met carriers compared to those with the Val/Val genotype [137-140]. There appears to be some evidence for this at a neuronal level as the Met allele has been associated with increases in mean diffusivity in significant clusters throughout the bilateral hemispheres in response to exercise, despite at baseline having reduced mean diffusivity throughout the grey and white matter in comparison to the Val/Val genotype [141]. Caldwell et al. [142] found that those with at least one copy of the Met allele reported greater motivation to continue exercising and less perceived exertion than those with the Val/Val genotype. This suggests that those with the Met allele may perceive exercise as more intrinsically rewarding and, therefore, may be more likely to engage in higher levels of physical activity than those with the Val/Val genotype [142]. However, some studies have found an increase in BDNF levels after exercising in the Val/Val genotype, which was not seen in Met allele carriers [143, 144]. Specifically, Chen et al. [143] found a decrease in anxiety and depressive-like behaviour in mice carrying the Met allele after physical activity compared to mice with the Val/Val genotype. Additionally, Watts et al. [145] found that exercise benefited cognition only in males of the Val/Val genotype. However, some studies have found no association between the Val66Met genotype and BDNF increases after exercise [146].

Overall, this research has a good distribution across age groups and sexes/genders, making the results more generalisable. However, further research comparing the difference between exercise durations, intensity and type is needed to indicate what type of exercise provides the most benefit and whether this differs between the genotypes. Moreover, a large proportion of the current literature on this topic focused on populations who were cognitively compromised (e.g., mild cognitive impairment or had a diagnosis of a neurodegenerative disorder) and therefore lacked generalisation to healthy populations.

11 VAL66MET, PTSD, FEAR CONDITIONING, AND PHYSICAL ACTIVITY

A limited amount of research has been conducted on the effect of the Val66Met polymorphism on fear conditioning or symptoms of PTSD and the moderative effects of physical activity. Some studies suggest that individuals with the Met allele benefit most from exercise in fear extinction recovery [147, 148]. In contrast, others suggest that those with the Val/Val genotype are more likely to show benefits compared to Met allele carriers [149]. Keyan and Bryant [147] found that exercise was associated with greater fear recovery only in those with the Met allele in a potentiated startle paradigm. Pitts et al. [148] found that Met allele carriers reported greater severity of lifetime and current symptoms of PTSD, specifically re-experiencing symptoms. They also found that Met allele carriers who had exercised had significantly lower severity of PTSD symptoms than those who had not; however, the same effect was not seen in those with the Val/Val genotype [148]. However, Keyan and Bryant [149] found an interaction between the Val/Val allele and cortisol response, which predicted stronger emotional memory in the exercise condition, demonstrating that the Val/Val genotype may have a greater response from exercise in their memory of emotional information. Therefore, the interaction between the Val66Met polymorphism, physical activity, fear conditioning, and extinction remains unclear.

However, the majority of these studies utilised small sample sizes or focused on different aspects of symptomology. The studies conducted by Keyan and Bryant [147, 149] focused on the impact of acute exercise following a conditioning and extinction paradigm. In contrast, Pitts investigated the correlation between PTSD symptoms and self-reported current engagement in physical activity. Additionally, the studies by Keyan and Bryant [149] and Pitts et al. [148] used subjective measures, such as self-reports, to analyse symptoms of PTSD, memory and level of engagement in physical activity. Studies using standardised laboratory-controlled assessment measures are needed to reduce the influence of extraneous variables on the results. Therefore, further research is needed on the direct impact of regular exercise and this polymorphism on fear conditioning and extinction.

CONCLUSION AND FUTURE DIRECTIONS

BDNF and its single-nucleotide polymorphism Val66Met have been associated with fear conditioning responses and PTSD susceptibility and symptom severity. There is some evidence to suggest a sex-specific genotype interaction, although studies analysing differences between the sexes are limited. This polymorphism has demonstrated differing effects at a structural, neuronal, cellular, and molecular level. Exercise has been shown to increase BDNF levels and improve mood, cognition and response to fear conditioning and extinction training. There is some evidence to suggest differing responses between the genotypes regarding their response to physical activity. However, small sample sizes, sampling biases, uncontrolled extraneous variables and methodological limitations may contribute to inconsistencies within the results across studies. Although the majority of the research appears to suggest that the Met allele is associated with impaired fear conditioning, higher susceptibility to PTSD, and a greater response to physical activity when assessing mood, cognition, and fear conditioning responses, there is increasing evidence to suggest that the Val/Val genotype may increase vulnerability and be more reactive to exercise-induced changes in BDNF levels.

Future research should investigate a sex-specific genotype interaction in response to physical activity in fear conditioning and extinction. Differences in the frequency and timing of exercise should also be explored (i.e., acute vs. regular exercise and exercise following fear learning vs. fear extinction training). Furthermore, the influence of a gene-environment interaction should be examined further.

ACKNOWLEDGEMENTS

Declared none.

LIST OF ABBREVIATIONS

7,8-DHF 7,8-Dihydroxyflavone

BDNF Brain-derived Neurotrophic Factor

CR Conditioned Fear Response

CS Conditioned Stimulus

CREB Cyclic AMP-responsive Element-binding Protein

DACC Dorsal Anterior Cingulate Cortex

DSM-5 Diagnostic and Statistical Manual of Mental Disorders, 5th Edition

GWAS Genome-wide Association Study

HPA Hypothalamic-pituitary-adrenal

IL Infralimbic Cortex

LTP Long-term Potentiation

Met Methionine

mPFC Medial Prefrontal Cortex

PL Prelimbic Cortex

PTSD Post-traumatic Stress Disorder

SNRI Selective Serotonin and Norepinephrine Reuptake Inhibitors

SSRI Selective Serotonin Reuptake Inhibitors

TrkB Tropomyosin-Related Kinase B

US Unconditioned Stimulus

Val Valine

vmPFC Ventromedial Prefrontal Cortex

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

None.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

Fig. (1) BDNF deficiency in BDNF heterozygous rats impairs fear acquisition (A) and leads to vulnerability to the effect of chronic exposure to the glucocorticoid stress hormone, corticosterone. BDNF heterozygous rats treated with corticosterone showed impaired fear extinction learning (B) and fear extinction memory (C). *p < 0.05 for difference in freezing compared to the corresponding wildtype group. Abbreviations: WT = wildtype control; HET = BDNF heterozygous; Contr = control treatment; CORT = corticosterone treatment in the drinking water. For methodological details and further results, see [56] from which this figure was adapted.

Fig. (2) Lack of effect of the BDNF Val66Met genotype on acquisition of conditioned fear (A), and context- and cue-induced freezing (B and C), open symbols are data from females, closed symbols are data from males). Of note, these animals were part of a study which used a chronic treatment protocol including daily intraperitoneal injections, which may have constituted additional stress and influenced underlying genotype differences. For methodological details and further results, see [91] from which this figure was adapted.

Fig. (3) BDNF protein levels, measured with ELISA, are increased in the ventral hippocampus of a BDNF Val66Met model following chronic exercise. This effect was most pronounced in Val/Val and Met/Met male rats and in Val/Met female rats. Data are mean ± SEM. **p < 0.05 for difference with sedentary controls of the same sex and genotype. For methodological details and additional results, see [134], from which this figure was adapted.
==== Refs
REFERENCES

1 Koenen K.C. Ratanatharathorn A. Ng L. McLaughlin K.A. Bromet E.J. Stein D.J. Karam E.G. Meron Ruscio A. Benjet C. Scott K. Atwoli L. Petukhova M. Lim C.C.W. Aguilar-Gaxiola S. Al-Hamzawi A. Alonso J. Bunting B. Ciutan M. de Girolamo G. Degenhardt L. Gureje O. Haro J.M. Huang Y. Kawakami N. Lee S. Navarro-Mateu F. Pennell B.E. Piazza M. Sampson N. ten Have M. Torres Y. Viana M.C. Williams D. Xavier M. Kessler R.C. Posttraumatic stress disorder in the world mental health surveys. Psychol. Med. 2017 47 13 2260 2274 10.1017/S0033291717000708 28385165
2 Lewis S.J. Arseneault L. Caspi A. Fisher H.L. Matthews T. Moffitt T.E. Odgers C.L. Stahl D. Teng J.Y. Danese A. The epidemiology of trauma and post-traumatic stress disorder in a representative cohort of young people in England and Wales. Lancet Psychiatry 2019 6 3 247 256 10.1016/S2215-0366(19)30031-8 30798897
3 Salehi M. Amanat M. Mohammadi M. Salmanian M. Rezaei N. Saghazadeh A. Garakani A. The prevalence of post-traumatic stress disorder related symptoms in Coronavirus outbreaks: A systematic-review and meta-analysis. J. Affect. Disord. 2021 282 527 538 10.1016/j.jad.2020.12.188 33433382
4 Woolgar F. Garfield H. Dalgleish T. Meiser-Stedman R. Systematic review and meta-analysis: prevalence of posttraumatic stress disorder in trauma-exposed preschool-aged children. J. Am. Acad. Child Adolesc. Psychiatry 2022 61 3 366 377 34242737
5 Olff M. Sex and gender differences in post-traumatic stress disorder: An update. Eur. J. Psychotraumatol. 2017 8 sup4 1351204 10.1080/20008198.2017.1351204
6 Diagnostic and statistical manual of mental disorders (DSM-5). 5th ed Arlington, VA American Psychiatric Association 2013
7 Hayes J.P. LaBar K.S. McCarthy G. Selgrade E. Nasser J. Dolcos F. Morey R.A. Reduced hippocampal and amygdala activity predicts memory distortions for trauma reminders in combat-related PTSD. J. Psychiatr. Res. 2011 45 5 660 669 21047644
8 Li H. Penzo M.A. Taniguchi H. Kopec C.D. Huang Z.J. Li B. Experience-dependent modification of a central amygdala fear circuit. Nat. Neurosci. 2013 16 3 332 339 10.1038/nn.3322 23354330
9 Nievergelt C.M. Maihofer A.X. Klengel T. Atkinson E.G. Chen C.Y. Choi K.W. Coleman J.R.I. Dalvie S. Duncan L.E. Gelernter J. Levey D.F. Logue M.W. Polimanti R. Provost A.C. Ratanatharathorn A. Stein M.B. Torres K. Aiello A.E. Almli L.M. Amstadter A.B. Andersen S.B. Andreassen O.A. Arbisi P.A. Ashley-Koch A.E. Austin S.B. Avdibegovic E. Babić D. Bækvad-Hansen M. Baker D.G. Beckham J.C. Bierut L.J. Bisson J.I. Boks M.P. Bolger E.A. Børglum A.D. Bradley B. Brashear M. Breen G. Bryant R.A. Bustamante A.C. Bybjerg-Grauholm J. Calabrese J.R. Caldas- de- Almeida, J.M.; Dale, A.M.; Daly, M.J.; Daskalakis, N.P.; Deckert, J.; Delahanty, D.L.; Dennis, M.F.; Disner, S.G.; Domschke, K.; Dzubur-Kulenovic, A.; Erbes, C.R.; Evans, A.; Farrer, L.A.; Feeny, N.C.; Flory, J.D.; Forbes, D.; Franz, C.E.; Galea, S.; Garrett, M.E.; Gelaye, B.; Geuze, E.; Gillespie, C.; Uka, A.G.; Gordon, S.D.; Guffanti, G.; Hammamieh, R.; Harnal, S.; Hauser, M.A.; Heath, A.C.; Hemmings, S.M.J.; Hougaard, D.M.; Jakovljevic, M.; Jett, M.; Johnson, E.O.; Jones, I.; Jovanovic, T.; Qin, X.J.; Junglen, A.G.; Karstoft, K.I.; Kaufman, M.L.; Kessler, R.C.; Khan, A.; Kimbrel, N.A.; King, A.P.; Koen, N.; Kranzler, H.R.; Kremen, W.S.; Lawford, B.R.; Lebois, L.A.M.; Lewis, C.E.; Linnstaedt, S.D.; Lori, A.; Lugonja, B.; Luykx, J.J.; Lyons, M.J.; Maples-Keller, J.; Marmar, C.; Martin, A.R.; Martin, N.G.; Maurer, D.; Mavissakalian, M.R.; McFarlane, A.; McGlinchey, R.E.; McLaughlin, K.A.; McLean, S.A.; McLeay, S.; Mehta, D.; Milberg, W.P.; Miller, M.W.; Morey, R.A.; Morris, C.P.; Mors, O.; Mortensen, P.B.; Neale, B.M.; Nelson, E.C.; Nordentoft, M.; Norman, S.B.; O’Donnell, M.; Orcutt, H.K.; Panizzon, M.S.; Peters, E.S.; Peterson, A.L.; Peverill, M.; Pietrzak, R.H.; Polusny, M.A.; Rice, J.P.; Ripke, S.; Risbrough, V.B.; Roberts, A.L.; Rothbaum, A.O.; Rothbaum, B.O.; Roy-Byrne, P.; Ruggiero, K.; Rung, A.; Rutten, B.P.F.; Saccone, N.L.; Sanchez, S.E.; Schijven, D.; Seedat, S.; Seligowski, A.V.; Seng, J.S.; Sheerin, C.M.; Silove, D.; Smith, A.K.; Smoller, J.W.; Sponheim, S.R.; Stein, D.J.; Stevens, J.S.; Sumner, J.A.; Teicher, M.H.; Thompson, W.K.; Trapido, E.; Uddin, M.; Ursano, R.J.; van den Heuvel, L.L.; Van Hooff, M.; Vermetten, E.; Vinkers, C.H.; Voisey, J.; Wang, Y.; Wang, Z.; Werge, T.; Williams, M.A.; Williamson, D.E.; Winternitz, S.; Wolf, C.; Wolf, E.J.; Wolff, J.D.; Yehuda, R.; Young, R.M.; Young, K.A.; Zhao, H.; Zoellner, L.A.; Liberzon, I.; Ressler, K.J.; Haas, M.; Koenen, K.C. International meta-analysis of PTSD genome-wide association studies identifies sex- and ancestry-specific genetic risk loci. Nat. Commun. 2019 10 1 4558 10.1038/s41467-019-12576-w 31594949
10 Friedman M.J. Keane T.M. Resick P.A. Amaya-Jackson L.M. Handbook of PTSD: Science and practice. 2nd ed New York Guilford Press 2014
11 Lancaster C. Teeters J. Gros D. Back S. Posttraumatic Stress Disorder: Overview of evidence-based assessment and treatment. J. Clin. Med. 2016 5 11 105 10.3390/jcm5110105 27879650
12 Flandreau E.I. Toth M. Animal models of PTSD: A critical review. Curr. Top. Behav. Neurosci. 2017 38 47 68 10.1007/7854_2016_65 28070873
13 Milad M.R. Rauch S.L. Pitman R.K. Quirk G.J. Fear extinction in rats: Implications for human brain imaging and anxiety disorders. Biol. Psychol. 2006 73 1 61 71 10.1016/j.biopsycho.2006.01.008 16476517
14 Fanselow M.S. What is conditioned fear? Trends Neurosci. 1984 7 12 460 462 10.1016/S0166-2236(84)80253-2
15 Milad M.R. Quirk G.J. Fear extinction as a model for translational neuroscience: Ten years of progress. Annu. Rev. Psychol. 2012 63 129 151 10.1146/annurev.psych.121208.131631 22129456
16 Andero R. Ressler K.J. Fear extinction and BDNF: Translating animal models of PTSD to the clinic. Genes Brain Behav. 2012 11 5 503 512 10.1111/j.1601-183X.2012.00801.x 22530815
17 Kim J.J. Jung M.W. Neural circuits and mechanisms involved in Pavlovian fear conditioning: A critical review. Neurosci. Biobehav. Rev. 2006 30 2 188 202 10.1016/j.neubiorev.2005.06.005 16120461
18 Milad M.R. Quirk G.J. Neurons in medial prefrontal cortex signal memory for fear extinction. Nature 2002 420 6911 70 74 10.1038/nature01138 12422216
19 Ravindran L.N. Stein M.B. Pharmacotherapy of PTSD: Premises, principles, and priorities. Brain Res. 2009 1293 24 39 10.1016/j.brainres.2009.03.037 19332035
20 Asnis G.M. Kohn S.R. Henderson M. Brown N.L. SSRIs versus non-SSRIs in post-traumatic stress disorder: An update with recommendations. Drugs 2004 64 4 383 404 10.2165/00003495-200464040-00004 14969574
21 Huang E.J. Reichardt L.F. Neurotrophins: Roles in neuronal development and function. Ann. Rev. Neurosci. 2001 24 1 677 736 11520916
22 Notaras M. van den Buuse M. Brain-derived neurotrophic factor and its role in stress-related disorders. Stress: Genetics, epigenetics, and genomics. Fink G. San Diego, Cambridge, Oxford Academic Press, Elsevier 2021 Vol. 4 253 261 10.1016/B978-0-12-813156-5.00023-6
23 Notaras M. Hill R. van den Buuse M. The BDNF gene Val66Met polymorphism as a modifier of psychiatric disorder susceptibility: progress and controversy. Mol. Psychiatry 2015 20 8 916 930 10.1038/mp.2015.27 25824305
24 Notaras M. van den Buuse M. Brain-Derived Neurotrophic Factor (BDNF): Novel insights into regulation and genetic variation. Neuroscientist 2019 25 5 434 454 10.1177/1073858418810142 30387693
25 Yang J. Siao C.J. Nagappan G. Marinic T. Jing D. McGrath K. Chen Z.Y. Mark W. Tessarollo L. Lee F.S. Lu B. Hempstead B.L. Neuronal release of proBDNF. Nat. Neurosci. 2009 12 2 113 115 10.1038/nn.2244 19136973
26 Nagappan G. Zaitsev E. Senatorov V.V. Jr Yang J. Hempstead B.L. Lu B. Control of extracellular cleavage of ProBDNF by high frequency neuronal activity. Proc. Natl. Acad. Sci. USA 2009 106 4 1267 1272 10.1073/pnas.0807322106 19147841
27 Notaras M. van den Buuse M. Neurobiology of BDNF in fear memory, sensitivity to stress, and stress-related disorders. Mol. Psychiatry 2020 25 10 2251 2274 10.1038/s41380-019-0639-2 31900428
28 Conner J.M. Lauterborn J.C. Yan Q. Gall C.M. Varon S. Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat CNS: evidence for anterograde axonal transport. J. Neurosci. 1997 17 7 2295 2313 10.1523/JNEUROSCI.17-07-02295.1997 9065491
29 Minichiello L. TrkB signalling pathways in LTP and learning. Nat. Rev. Neurosci. 2009 10 12 850 860 10.1038/nrn2738 19927149
30 Miranda M. Morici J.F. Zanoni M.B. Bekinschtein P. Brain-Derived Neurotrophic Factor: A key molecule for memory in the healthy and the pathological brain. Front. Cell. Neurosci. 2019 13 363 10.3389/fncel.2019.00363 31440144
31 Figurov A. Pozzo-Miller L.D. Olafsson P. Wang T. Lu B. Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus. Nature 1996 381 6584 706 709 10.1038/381706a0 8649517
32 Sasi M. Vignoli B. Canossa M. Blum R. Neurobiology of local and intercellular BDNF signaling. Pflugers Arch. 2017 469 5-6 593 610 10.1007/s00424-017-1964-4 28280960
33 Hill R.A. van den Buuse M. Sex-dependent and region-specific changes in TrkB signaling in BDNF heterozygous mice. Brain Res. 2011 1384 51 60 10.1016/j.brainres.2011.01.060 21281620
34 Klug M. Hill R.A. Choy K.H.C. Kyrios M. Hannan A.J. van den Buuse M. Long-term behavioral and NMDA receptor effects of young-adult corticosterone treatment in BDNF heterozygous mice. Neurobiol. Dis. 2012 46 3 722 731 10.1016/j.nbd.2012.03.015 22426399
35 Montkowski A. Holsboer F. Intact spatial learning and memory in transgenic mice with reduced BDNF. Neuroreport 1997 8 3 779 782 10.1097/00001756-199702100-00040 9106766
36 Gray J. Yeo G.S.H. Cox J.J. Morton J. Adlam A.L.R. Keogh J.M. Yanovski J.A. El Gharbawy A. Han J.C. Tung Y.C.L. Hodges J.R. Raymond F.L. O’Rahilly S. Farooqi I.S. Hyperphagia, severe obesity, impaired cognitive function, and hyperactivity associated with functional loss of one copy of the brain-derived neurotrophic factor (BDNF) gene. Diabetes 2006 55 12 3366 3371 10.2337/db06-0550 17130481
37 Gray J. Yeo G. Hung C. Keogh J. Clayton P. Banerjee K. McAulay A. O’Rahilly S. Farooqi I.S. Functional characterization of human NTRK2 mutations identified in patients with severe early-onset obesity. Int. J. Obes. 2007 31 2 359 364 10.1038/sj.ijo.0803390
38 Yeo G.S.H. Connie Hung C.C. Rochford J. Keogh J. Gray J. Sivaramakrishnan S. O’Rahilly S. Farooqi I.S. A de novo mutation affecting human TrkB associated with severe obesity and developmental delay. Nat. Neurosci. 2004 7 11 1187 1189 10.1038/nn1336 15494731
39 Arosio B. Guerini F.R. Voshaar R.C.O. Aprahamian I. Blood Brain-Derived Neurotrophic Factor (BDNF) and Major Depression: Do we have a translational perspective? Front. Behav. Neurosci. 2021 15 626906 10.3389/fnbeh.2021.626906 33643008
40 Arumugam V. John V. Augustine N. Jacob T. Joy S. Sen S. Sen T. The impact of antidepressant treatment on brain-derived neurotrophic factor level: An evidence-based approach through systematic review and meta-analysis. Indian J. Pharmacol. 2017 49 3 236 242 10.4103/ijp.IJP_700_16 29033483
41 Casarotto P.C. Girych M. Fred S.M. Kovaleva V. Moliner R. Enkavi G. Biojone C. Cannarozzo C. Sahu M.P. Kaurinkoski K. Brunello C.A. Steinzeig A. Winkel F. Patil S. Vestring S. Serchov T. Diniz C.R.A.F. Laukkanen L. Cardon I. Antila H. Rog T. Piepponen T.P. Bramham C.R. Normann C. Lauri S.E. Saarma M. Vattulainen I. Castrén E. Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. Cell 2021 184 5 1299 1313.e19 10.1016/j.cell.2021.01.034 33606976
42 Rosas-Vidal L.E. Do-Monte F.H. Sotres-Bayon F. Quirk G.J. Hippocampal--prefrontal BDNF and memory for fear extinction. Neuropsychopharmacology 2014 39 9 2161 2169 10.1038/npp.2014.64 24625752
43 Kataoka T. Fuchikami M. Nojima S. Nagashima N. Araki M. Omura J. Miyagi T. Okamoto Y. Morinobu S. Combined brain-derived neurotrophic factor with extinction training alleviate impaired fear extinction in an animal model of post-traumatic stress disorder. Genes Brain Behav. 2018 12520 10.1111/gbb.12520 30246290
44 Chaaya N. Wang J. Jacques A. Beecher K. Chaaya M. Battle A.R. Johnson L.R. Chehrehasa F. Belmer A. Bartlett S.E. Contextual fear memory maintenance changes expression of pMAPK, BDNF and IBA-1 in the prelimbic cortex in a layer-specific manner. Front. Neural Circuits 2021 15 660199 10.3389/fncir.2021.660199 34295224
45 Peters J. Dieppa-Perea L.M. Melendez L.M. Quirk G.J. Induction of fear extinction with hippocampal-infralimbic BDNF. Science 2010 328 5983 1288 1290 10.1126/science.1186909 20522777
46 Chang S.H. Yu Y.H. He A. Ou C.Y. Shyu B.C. Huang A.C.W. BDNF protein and BDNF mRNA expression of the medial prefrontal cortex, amygdala, and hippocampus during situational reminder in the PTSD animal model. Behav. Neurol. 2021 2021 1 13 10.1155/2021/6657716 33763156
47 Kirtley A. Thomas K.L. The exclusive induction of extinction is gated by BDNF. Learn. Mem. 2010 17 12 612 619 10.1101/lm.1877010 21127000
48 Radiske A. Rossato J.I. Köhler C.A. Gonzalez M.C. Medina J.H. Cammarota M. Requirement for BDNF in the reconsolidation of fear extinction. J. Neurosci. 2015 35 16 6570 6574 10.1523/JNEUROSCI.4093-14.2015 25904806
49 Chaaya N. Jacques A. Belmer A. Beecher K. Ali S.A. Chehrehasa F. Battle A.R. Johnson L.R. Bartlett S.E. Contextual fear conditioning alter microglia number and morphology in the rat dorsal hippocampus. Front. Cell. Neurosci. 2019 13 214 10.3389/fncel.2019.00214 31139053
50 Endres T. Lessmann V. Age-dependent deficits in fear learning in heterozygous BDNF knock-out mice. Learn. Mem. 2012 19 12 561 570 10.1101/lm.028068.112 23154927
51 Meis S. Endres T. Munsch T. Lessmann V. The relation between long-term synaptic plasticity at glutamatergic synapses in the amygdala and fear learning in adult heterozygous BDNF-knockout Mice. Cereb. Cortex 2018 28 4 1195 1208 10.1093/cercor/bhx032 28184413
52 Psotta L. Lessmann V. Endres T. Impaired fear extinction learning in adult heterozygous BDNF knock-out mice. Neurobiol. Learn. Mem. 2013 103 34 38 10.1016/j.nlm.2013.03.003 23578839
53 Hill J.L. Hardy N.F. Jimenez D.V. Maynard K.R. Kardian A.S. Pollock C.J. Schloesser R.J. Martinowich K. Loss of promoter IV-driven BDNF expression impacts oscillatory activity during sleep, sensory information processing and fear regulation. Transl. Psychiatry 2016 6 8 e873 10.1038/tp.2016.153 27552586
54 Choi D.C. Maguschak K.A. Ye K. Jang S.W. Myers K.M. Ressler K.J. Prelimbic cortical BDNF is required for memory of learned fear but not extinction or innate fear. Proc. Natl. Acad. Sci. USA 2010 107 6 2675 2680 10.1073/pnas.0909359107 20133801
55 McEwen B.S. Bowles N.P. Gray J.D. Hill M.N. Hunter R.G. Karatsoreos I.N. Nasca C. Mechanisms of stress in the brain. Nat. Neurosci. 2015 18 10 1353 1363 10.1038/nn.4086 26404710
56 Gururajan A. Hill R.A. van den Buuse M. Brain-derived neurotrophic factor heterozygous mutant rats show selective cognitive changes and vulnerability to chronic corticosterone treatment. Neuroscience 2015 284 297 310 10.1016/j.neuroscience.2014.10.009 25445195
57 Wu Y.C. Hill R.A. Gogos A. van den Buuse M. Sex differences and the role of estrogen in animal models of schizophrenia: Interaction with BDNF. Neuroscience 2013 239 67 83 10.1016/j.neuroscience.2012.10.024 23085218
58 Baker-Andresen D. Flavell C.R. Li X. Bredy T.W. Activation of BDNF signaling prevents the return of fear in female mice. Learn. Mem. 2013 20 5 237 240 10.1101/lm.029520.112 23589089
59 Aksu S. Unlu G. Kardesler A.C. Cakaloz B. Aybek H. Altered levels of brain-derived neurotrophic factor, proBDNF and tissue plasminogen activator in children with posttraumatic stress disorder. Psychiatry Res. 2018 268 478 483 10.1016/j.psychres.2018.07.013 30142554
60 Stratta P. Sanità P. Bonanni R.L. de Cataldo S. Angelucci A. Rossi R. Origlia N. Domenici L. Carmassi C. Piccinni A. Dell’Osso L. Rossi A. Clinical correlates of plasma brain-derived neurotrophic factor in post-traumatic stress disorder spectrum after a natural disaster. Psychiatry Res. 2016 244 165 170 10.1016/j.psychres.2016.07.019 27479108
61 Bücker J. Fries G.R. Kapczinski F. Post R.M. Yatham L.N. Vianna P. Bogo Chies J.A. Gama C.S. Magalhães P.V. Aguiar B.W. Pfaffenseller B. Kauer-Sant’Anna, M. Brain-derived neurotrophic factor and inflammatory markers in school-aged children with early trauma. Acta Psychiatr. Scand. 2015 131 5 360 368 10.1111/acps.12358 25401224
62 Matsuoka Y. Nishi D. Noguchi H. Kim Y. Hashimoto K. Longitudinal changes in serum brain-derived neurotrophic factor in accident survivors with posttraumatic stress disorder. Neuropsychobiology 2013 68 1 44 50 10.1159/000350950 23774996
63 Su S. Xiao Z. Lin Z. Qiu Y. Jin Y. Wang Z. Plasma brain-derived neurotrophic factor levels in patients suffering from post-traumatic stress disorder. Psychiatry Res. 2015 229 1-2 365 369 10.1016/j.psychres.2015.06.038 26160204
64 Howie H. Rijal C.M. Ressler K.J. A review of epigenetic contributions to post-traumatic stress disorder. Dialogues Clin. Neurosci. 2019 21 4 417 428 10.31887/DCNS.2019.21.4/kressler 31949409
65 Kim T.Y. Kim S.J. Chung H.G. Choi J.H. Kim S.H. Kang J.I. Epigenetic alterations of the BDNF gene in combat-related post-traumatic stress disorder. Acta Psychiatr. Scand. 2017 135 2 170 179 10.1111/acps.12675 27886370
66 Pilakka-Kanthikeel S. Atluri V.S. Sagar V. Saxena S.K. Nair M. Targeted brain derived neurotropic factors (BDNF) delivery across the blood-brain barrier for neuro-protection using magnetic nano carriers: an in-vitro study. PLoS One 2013 8 4 e62241 23653680
67 Mahan A.L. Ressler K.J. Fear conditioning, synaptic plasticity and the amygdala: implications for posttraumatic stress disorder. Trends Neurosci. 2012 35 1 24 35 10.1016/j.tins.2011.06.007 21798604
68 Zeng Y. Liu Y. Wu M. Liu J. Hu Q. Activation of TrkB by 7,8-dihydroxyflavone prevents fear memory defects and facilitates amygdalar synaptic plasticity in aging. J. Alzheimers Dis. 2012 31 4 765 778 10.3233/JAD-2012-120886 22710915
69 Andero R. Heldt S.A. Ye K. Liu X. Armario A. Ressler K.J. Effect of 7,8-dihydroxyflavone, a small-molecule TrkB agonist, on emotional learning. Am. J. Psychiatry 2011 168 2 163 172 21123312
70 Flavell C.R. Lambert E.A. Winters B.D. Bredy T.W. Mechanisms governing the reactivation-dependent destabilization of memories and their role in extinction. Front. Behav. Neurosci. 2013 7 214 10.3389/fnbeh.2013.00214 24421762
71 Klein R. Nanduri V. Jing S. Lamballe F. Tapley P. Bryant S. Cordon-Cardo C. Jones K.R. Reichardt L.F. Barbacid M. The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. Cell 1991 66 2 395 403 10.1016/0092-8674(91)90628-C 1649702
72 Soppet D. Escandon E. Maragos J. Middlemas D.S. Raid S.W. Blair J. Burton L.E. Stanton B.R. Kaplan D.R. Hunter T. Nikolics K. Parade L.F. The neurotrophic factors brain-derived neurotrophic factor and neurotrophin-3 are ligands for the trkB tyrosine kinase receptor. Cell 1991 65 5 895 903 10.1016/0092-8674(91)90396-G 1645620
73 Chen Z.Y. Ieraci A. Teng H. Dall H. Meng C.X. Herrera D.G. Nykjaer A. Hempstead B.L. Lee F.S. Sortilin controls intracellular sorting of brain-derived neurotrophic factor to the regulated secretory pathway. J. Neurosci. 2005 25 26 6156 6166 10.1523/JNEUROSCI.1017-05.2005 15987945
74 Yang M. Lim Y. Li X. Zhong J.H. Zhou X.F. Precursor of brain-derived neurotrophic factor (proBDNF) forms a complex with Huntingtin-associated protein-1 (HAP1) and sortilin that modulates proBDNF trafficking, degradation, and processing. J. Biol. Chem. 2011 286 18 16272 16284 10.1074/jbc.M110.195347 21357693
75 Chen Z.Y. Jing D. Bath K.G. Ieraci A. Khan T. Siao C.J. Herrera D.G. Toth M. Yang C. McEwen B.S. Hempstead B.L. Lee F.S. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 2006 314 5796 140 143 10.1126/science.1129663 17023662
76 Mercado N.M. Stancati J.A. Sortwell C.E. Mueller R.L. Boezwinkle S.A. Duffy M.F. Fischer D.L. Sandoval I.M. Manfredsson F.P. Collier T.J. Steece-Collier K. The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in rats. Neurobiol. Dis. 2021 148 105175 10.1016/j.nbd.2020.105175 33188920
77 Egan M.F. Kojima M. Callicott J.H. Goldberg T.E. Kolachana B.S. Bertolino A. Zaitsev E. Gold B. Goldman D. Dean M. Lu B. Weinberger D.R. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003 112 2 257 269 10.1016/S0092-8674(03)00035-7 12553913
78 Petryshen T.L. Sabeti P.C. Aldinger K.A. Fry B. Fan J.B. Schaffner S.F. Waggoner S.G. Tahl A.R. Sklar P. Population genetic study of the brain-derived neurotrophic factor (BDNF) gene. Mol. Psychiatry 2010 15 8 810 815 10.1038/mp.2009.24 19255578
79 Dincheva I. Pattwell S.S. Tessarollo L. Bath K.G. Lee F.S. BDNF modulates contextual fear learning during adolescence. Dev. Neurosci. 2014 36 3-4 269 276 10.1159/000358824 24992985
80 Felmingham K.L. Zuj D.V. Hsu K.C.M. Nicholson E. Palmer M.A. Stuart K. Vickers J.C. Malhi G.S. Bryant R.A. The BDNF Val66Met polymorphism moderates the relationship between Posttraumatic Stress Disorder and fear extinction learning. Psychoneuroendocrinology 2018 91 142 148 10.1016/j.psyneuen.2018.03.002 29550677
81 Giza J.I. Kim J. Meyer H.C. Anastasia A. Dincheva I. Zheng C.I. Lopez K. Bains H. Yang J. Bracken C. Liston C. Jing D. Hempstead B.L. Lee F.S. The BDNF val66met prodomain disassembles dendritic spines altering fear extinction circuitry and behavior. Neuron 2018 99 1 163 178.e6 10.1016/j.neuron.2018.05.024 29909994
82 Mühlberger A. Andreatta M. Ewald H. Glotzbach-Schoon E. Tröger C. Baumann C. Reif A. Deckert J. Pauli P. The BDNF Val66Met polymorphism modulates the generalization of cued fear responses to a novel context. Neuropsychopharmacology 2014 39 5 1187 1195 10.1038/npp.2013.320 24247044
83 Soliman F. Glatt C.E. Bath K.G. Levita L. Jones R.M. Pattwell S.S. Jing D. Tottenham N. Amso D. Somerville L.H. Voss H.U. Glover G. Ballon D.J. Liston C. Teslovich T. Van Kempen T. Lee F.S. Casey B.J. A genetic variant BDNF polymorphism alters extinction learning in both mouse and human. Science 2010 327 5967 863 866 10.1126/science.1181886 20075215
84 Lonsdorf T.B. Golkar A. Lindström K.M. Haaker J. Öhman A. Schalling M. Ingvar M. BDNF val66met affects neural activation pattern during fear conditioning and 24 h delayed fear recall. Soc. Cogn. Affect. Neurosci. 2015 10 5 664 671 10.1093/scan/nsu102 25103087
85 Lonsdorf T.B. Weike A.I. Golkar A. Schalling M. Hamm A.O. Öhman A. Amygdala-dependent fear conditioning in humans is modulated by the BDNFval66met polymorphism. Behav. Neurosci. 2010 124 1 9 15 10.1037/a0018261 20141276
86 Asthana M.K. Brunhuber B. Mühlberger A. Reif A. Schneider S. Herrmann M.J. Preventing the return of fear using reconsolidation update mechanisms depends on the met-allele of the brain derived neurotrophic factor val66met polymorphism. Int. J. Neuropsychopharmacol. 2015 19 6 pyv137 10.1093/ijnp/pyv137 26721948
87 Jaehne E.J. Kent J.N. Antolasic E.J. Wright B.J. Spiers J.G. Creutzberg K.C. De Rosa F. Riva M.A. Sortwell C.E. Collier T.J. van den Buuse M. Behavioral phenotyping of a rat model of the BDNF Val66Met polymorphism reveals selective impairment of fear memory. Transl. Psychiatry 2022 12 1 93 10.1038/s41398-022-01858-5 35256586
88 Long V.A. Fanselow M.S. Stress-enhanced fear learning in rats is resistant to the effects of immediate massed extinction. Stress 2012 15 6 627 636 10.3109/10253890.2011.650251 22176467
89 Raju S. Notaras M. Grech A.M. Schroeder A. van den Buuse M. Hill R.A. BDNF Val66Met genotype and adolescent glucocorticoid treatment induce sex-specific disruptions to fear extinction and amygdala GABAergic interneuron expression in mice. Horm. Behav. 2022 144 105231 10.1016/j.yhbeh.2022.105231 35779519
90 Notaras M. Hill R. Gogos J.A. van den Buuse M. BDNF Val66Met genotype determines hippocampus-dependent behavior via sensitivity to glucocorticoid signaling. Mol. Psychiatry 2016 21 6 730 732 10.1038/mp.2015.152 26821977
91 Corrone M. Ratnayake R. De Oliveira N. Jaehne E.J. van den Buuse M. Methamphetamine-induced locomotor sensitization in mice is not associated with deficits in a range of cognitive, affective and social behaviours: Interaction with brain-derived neurotrophic factor (BDNF) Val66Met. Behav. Pharmacol. 2022 34 1 20 36 36373697
92 Richter-Levin G. Stork O. Schmidt M.V. Animal models of PTSD: A challenge to be met. Mol. Psychiatry 2019 24 8 1135 1156 10.1038/s41380-018-0272-5 30816289
93 Osterburg A.R. Hexley P. Supp D.M. Robinson C.T. Noel G. Ogle C. Boyce S.T. Aronow B.J. Babcock G.F. Concerns over interspecies transcriptional comparisons in mice and humans after trauma. Proc. Natl. Acad. Sci. USA 2013 110 36 E3370 10.1073/pnas.1306033110 23847210
94 Cohen H. Geva A.B. Matar M.A. Zohar J. Kaplan Z. Post-traumatic stress behavioural responses in inbred mouse strains: can genetic predisposition explain phenotypic vulnerability? Int. J. Neuropsychopharmacol. 2008 11 3 331 349 10.1017/S1461145707007912 17655807
95 Shansky R.M. Sex differences in PTSD resilience and susceptibility: Challenges for animal models of fear learning. Neurobiol. Stress 2015 1 60 65 25729759
96 Dai W. Kaminga A.C. Wu X. Wen S.W. Tan H. Yan J. Deng J. Lai Z. Liu A. Brain-derived neurotropic factor val66met polymorphism and posttraumatic stress disorder among survivors of the 1998 Dongting lake flood in China. BioMed Res. Int. 2017 2017 1 9 10.1155/2017/4569698 28589140
97 Guo J.C. Yang Y.J. Zheng J.F. Guo M. Wang X.D. Gao Y.S. Fu L.Q. Jiang X.L. Fu L.M. Huang T. Functional rs6265 polymorphism in the brain‐derived neurotrophic factor gene confers protection against neurocognitive dysfunction in posttraumatic stress disorder among Chinese patients with hepatocellular carcinoma. J. Cell. Biochem. 2019 120 6 10434 10443 10.1002/jcb.28328 30659644
98 Young D.A. Neylan T.C. O’Donovan A. Metzler T. Richards A. Ross J.A. Inslicht S.S. The interaction of BDNF Val66Met, PTSD, and child abuse on psychophysiological reactivity and HPA axis function in a sample of Gulf War Veterans. J. Affect. Disord. 2018 235 52 60 10.1016/j.jad.2018.04.004 29649711
99 Li R.H. Fan M. Hu M.S. Ran M.S. Fang D.Z. Reduced severity of posttraumatic stress disorder associated with Val allele of Val66Met polymorphism at brain-derived neurotrophic factor gene among Chinese adolescents after Wenchuan earthquake. Psychophysiology 2016 53 5 705 711 10.1111/psyp.12603 26751724
100 Zhang L. Benedek D.M. Fullerton C.S. Forsten R.D. Naifeh J.A. Li X.X. Hu X.Z. Li H. Jia M. Xing G.Q. Benevides K.N. Ursano R.J. PTSD risk is associated with BDNF Val66Met and BDNF overexpression. Mol. Psychiatry 2014 19 1 8 10 10.1038/mp.2012.180 23319005
101 Nedic Erjavec G. Nikolac Perkovic M. Tudor L. Uzun S. Kovacic Petrovic Z. Konjevod M. Sagud M. Kozumplik O. Svob Strac D. Peraica T. Mimica N. Havelka M.A. Zilic D. Pivac N. Moderating effects of BDNF genetic variants and smoking on cognition in PTSD veterans. Biomolecules 2021 11 5 641 10.3390/biom11050641 33926045
102 Dretsch M.N. Williams K. Emmerich T. Crynen G. Ait-Ghezala G. Chaytow H. Mathura V. Crawford F.C. Iverson G.L. Brain‐derived neurotropic factor polymorphisms, traumatic stress, mild traumatic brain injury, and combat exposure contribute to postdeployment traumatic stress. Brain Behav. 2016 6 1 e00392 10.1002/brb3.392 27110438
103 Pivac N. Kozaric-Kovacic D. Grubisic-Ilic M. Nedic G. Rakos I. Nikolac M. Blazev M. Muck-Seler D. The association between brain-derived neurotrophic factor Val66Met variants and psychotic symptoms in posttraumatic stress disorder. World J. Biol. Psychiatry 2012 13 4 306 311 10.3109/15622975.2011.582883 21728904
104 Felmingham K.L. Dobson-Stone C. Schofield P.R. Quirk G.J. Bryant R.A. The brain-derived neurotrophic factor val66met polymorphism predicts response to exposure therapy in posttraumatic stress disorder. Biol. Psychiatry 2013 73 11 1059 1063 10.1016/j.biopsych.2012.10.033 23312562
105 Lyoo I.K. Kim J.E. Yoon S.J. Hwang J. Bae S. Kim D.J. The neurobiological role of the dorsolateral prefrontal cortex in recovery from trauma. Longitudinal brain imaging study among survivors of the South Korean subway disaster. Arch. Gen. Psychiatry 2011 68 7 701 713 10.1001/archgenpsychiatry.2011.70 21727254
106 Jin M.J. Jeon H. Hyun M.H. Lee S.H. Influence of childhood trauma and brain-derived neurotrophic factor Val66Met polymorphism on posttraumatic stress symptoms and cortical thickness. Sci. Rep. 2019 9 1 6028 10.1038/s41598-019-42563-6 30988377
107 van den Heuvel L. Suliman S. Malan-Müller S. Hemmings S. Seedat S. Brain-derived neurotrophic factor Val66met polymorphism and plasma levels in road traffic accident survivors. Anxiety Stress Coping 2016 29 6 616 629 10.1080/10615806.2016.1163545 26999419
108 Valente N.L.M. Vallada H. Cordeiro Q. Miguita K. Bressan R.A. Andreoli S.B. Mari J.J. Mello M.F. Candidate-gene approach in posttraumatic stress disorder after urban violence: Association analysis of the genes encoding serotonin transporter, dopamine transporter, and BDNF. J. Mol. Neurosci. 2011 44 1 59 67 10.1007/s12031-011-9513-7 21491204
109 Bruenig D. Lurie J. Morris C.P. Harvey W. Lawford B. Young R.M. Voisey J. A case-control study and meta-analysis reveal BDNF val66met is a possible risk factor for PTSD. Neural Plast. 2016 2016 1 10 10.1155/2016/6979435 27413557
110 Guo J.C. Yang Y.J. Guo M. Wang X.D. Juan Y. Gao Y.S. Fu L.Q. Jiang X.L. Fu L.M. Huang T. Guo; Yang, Y.-J.; Guo, M.; Wang, X.-D.; Juan, Y.; Gao, Y.-S.; Fu, L.-Q.; Jiang, X.-L.; Fu, L.-M.; Huang, T., Correlations of four genetic single nucleotide polymorphisms in brain-derived neurotrophic factor with posttraumatic stress disorder. Psychiatry Investig. 2018 15 4 407 412 10.30773/pi.2017.06.17.1 29551049
111 Bountress K.E. Bacanu S.A. Tomko R.L. Korte K.J. Hicks T. Sheerin C. Lind M.J. Marraccini M. Nugent N. Amstadter A.B. The effects of a BDNF val66met polymorphism on posttraumatic stress disorder: A meta-analysis. Neuropsychobiology 2017 76 3 136 142 10.1159/000489407 29874672
112 Tudor L. Konjevod M. Nikolac Perkovic M. Svob Strac D. Nedic Erjavec G. Uzun S. Kozumplik O. Sagud M. Kovacic Petrovic Z. Pivac N. Genetic variants of the brain-derived neurotrophic factor and metabolic indices in veterans with posttraumatic stress disorder. Front. Psychiatry 2018 9 637 10.3389/fpsyt.2018.00637 30542302
113 Dinoff A. Herrmann N. Swardfager W. Lanctôt K.L. The effect of acute exercise on blood concentrations of brain-derived neurotrophic factor in healthy adults: A meta-analysis. Eur. J. Neurosci. 2017 46 1 1635 1646 10.1111/ejn.13603 28493624
114 Patki G. Li L. Allam F. Solanki N. Dao A.T. Alkadhi K. Salim S. Moderate treadmill exercise rescues anxiety and depression-like behavior as well as memory impairment in a rat model of posttraumatic stress disorder. Physiol. Behav. 2014 130 47 53 10.1016/j.physbeh.2014.03.016 24657739
115 Vaynman S. Ying Z. Gomez-Pinilla F. Hippocampal BDNF mediates the efficacy of exercise on synaptic plasticity and cognition. Eur. J. Neurosci. 2004 20 10 2580 2590 10.1111/j.1460-9568.2004.03720.x 15548201
116 Fang Z.H. Lee C.H. Seo M.K. Cho H. Lee J.G. Lee B.J. Park S.W. Kim Y.H. Effect of treadmill exercise on the BDNF-mediated pathway in the hippocampus of stressed rats. Neurosci. Res. 2013 76 4 187 194 10.1016/j.neures.2013.04.005 23665137
117 Lu J. Xu Y. Hu W. Gao Y. Ni X. Sheng H. Liu Y. Exercise ameliorates depression-like behavior and increases hippocampal BDNF level in ovariectomized rats. Neurosci. Lett. 2014 573 13 18 10.1016/j.neulet.2014.04.053 24813109
118 Marais L. Stein D.J. Daniels W.M.U. Exercise increases BDNF levels in the striatum and decreases depressive-like behavior in chronically stressed rats. Metab. Brain Dis. 2009 24 4 587 597 10.1007/s11011-009-9157-2 19844781
119 Marlatt M.W. Potter M.C. Lucassen P.J. van Praag H. Running throughout middle-age improves memory function, hippocampal neurogenesis, and BDNF levels in female C57BL/6J mice. Dev. Neurobiol. 2012 72 6 943 952 10.1002/dneu.22009 22252978
120 Shafia S. Vafaei A.A. Samaei S.A. Bandegi A.R. Rafiei A. Valadan R. Hosseini-Khah Z. Mohammadkhani R. Rashidy-Pour A. Effects of moderate treadmill exercise and fluoxetine on behavioural and cognitive deficits, hypothalamic-pituitary-adrenal axis dysfunction and alternations in hippocampal BDNF and mRNA expression of apoptosis – related proteins in a rat model of post-traumatic stress disorder. Neurobiol. Learn. Mem. 2017 139 165 178 10.1016/j.nlm.2017.01.009 28137660
121 Neeper S.A. Gómez-Pinilla F. Choi J. Cotman C.W. Physical activity increases mRNA for brain-derived neurotrophic factor and nerve growth factor in rat brain. Brain Res. 1996 726 1-2 49 56 10.1016/0006-8993(96)00273-9 8836544
122 Sun L. Cui K. Xing F. Liu X. Akt dependent adult hippocampal neurogenesis regulates the behavioral improvement of treadmill running to mice model of post-traumatic stress disorder. Behav. Brain Res. 2020 379 112375 10.1016/j.bbr.2019.112375 31759046
123 van Praag H. Neurogenesis and exercise: past and future directions. Neuromol. Med. 2008 10 2 128 140 10.1007/s12017-008-8028-z 18286389
124 Nowacka-Chmielewska M. Grabowska K. Grabowski M. Meybohm P. Burek M. Małecki A. Running from stress: Neurobiological mechanisms of exercise-induced stress resilience. Int. J. Mol. Sci. 2022 23 21 13348 10.3390/ijms232113348 36362131
125 Ishikawa R. Uchida C. Kitaoka S. Furuyashiki T. Kida S. Improvement of PTSD-like behavior by the forgetting effect of hippocampal neurogenesis enhancer memantine in a social defeat stress paradigm. Mol. Brain 2019 12 1 68 10.1186/s13041-019-0488-6 31370877
126 Schoenfeld T.J. Rhee D. Martin L. Smith J.A. Sonti A.N. Padmanaban V. Cameron H.A. New neurons restore structural and behavioral abnormalities in a rat model of PTSD. Hippocampus 2019 29 9 848 861 10.1002/hipo.23087 30865372
127 Powers M.B. Medina J.L. Burns S. Kauffman B.Y. Monfils M. Asmundson G.J. Diamond A. McIntyre C. Smits J.A. Exercise augmentation of exposure therapy for PTSD: Rationale and pilot efficacy data. Cogn. Behav. Ther. 2015 44 4 314 327 25706090
128 Crombie K.M. Sartin-Tarm A. Sellnow K. Ahrenholtz R. Lee S. Matalamaki M. Almassi N.E. Hillard C.J. Koltyn K.F. Adams T.G. Cisler J.M. Exercise-induced increases in Anandamide and BDNF during extinction consolidation contribute to reduced threat following reinstatement: Preliminary evidence from a randomized controlled trial. Psychoneuroendocrinology 2021 132 105355 10.1016/j.psyneuen.2021.105355 34280820
129 Szuhany K.L. Bugatti M. Otto M.W. A meta-analytic review of the effects of exercise on brain-derived neurotrophic factor. J. Psychiatr. Res. 2015 60 56 64 10.1016/j.jpsychires.2014.10.003 25455510
130 Hu S. Tucker L. Wu C. Yang L. Beneficial effects of exercise on depression and anxiety during the COVID-19 pandemic: A narrative review. Front. Psychiatry 2020 11 587557 10.3389/fpsyt.2020.587557 33329133
131 Ruiz-González D. Hernández-Martínez A. Valenzuela P.L. Morales J.S. Soriano-Maldonado A. Effects of physical exercise on plasma brain-derived neurotrophic factor in neurodegenerative disorders: A systematic review and meta-analysis of randomized controlled trials. Neurosci. Biobehav. Rev. 2021 128 394 405 10.1016/j.neubiorev.2021.05.025 34087277
132 Cavalcante B.R.R. Improta-Caria A.C. Melo V.H. De Sousa R.A.L. Exercise-linked consequences on epilepsy. Epilepsy Behav. 2021 121 Pt A 108079 10.1016/j.yebeh.2021.108079 34058490
133 Murawska-Ciałowicz E. Wiatr M. Ciałowicz M. Gomes de Assis G. Borowicz W. Rocha-Rodrigues S. Paprocka-Borowicz M. Marques A. BDNF impact on biological markers of depression - Role of physical exercise and training. Int. J. Environ. Res. Public Health 2021 18 14 7553 10.3390/ijerph18147553 34300001
134 Jaehne E.J. Kent J.N. Lam N. Schonfeld L. Spiers J.G. Begni V. De Rosa F. Riva M.A. van den Buuse M. Chronic running‐wheel exercise from adolescence leads to increased anxiety and depression‐like phenotypes in adulthood in rats: Effects on stress markers and interaction with BDNF Val66Met genotype. Dev. Psychobiol. 2023 65 1 e22347 10.1002/dev.22347 36567651
135 Nascimento C.M.C. Pereira J.R. Pires de Andrade L. Garuffi M. Ayan C. Kerr D.S. Talib L.L. Cominetti M.R. Stella F. Physical exercise improves peripheral BDNF levels and cognitive functions in mild cognitive impairment elderly with different bdnf Val66Met genotypes. J. Alzheimers Dis. 2014 43 1 81 91 10.3233/JAD-140576 25062900
136 Rahman M.S. Millischer V. Zeebari Z. Forsell Y. Lavebratt C. BDNF Val66Met and childhood adversity on response to physical exercise and internet-based cognitive behavioural therapy in depressed Swedish adults. J. Psychiatr. Res. 2017 93 50 58 28578208
137 Kim J.M. Stewart R. Bae K.Y. Kim S.W. Yang S.J. Park K.H. Shin I.S. Yoon J.S. Role of BDNF val66met polymorphism on the association between physical activity and incident dementia. Neurobiol. Aging 2011 32 3 551.e5 12 10.1016/j.neurobiolaging.2010.01.018
138 Liu T. Canon M.D. Shen L. Marples B.A. Colton J.P. Lo W.J. Gray M. Li C. The influence of the BDNF Val66Met polymorphism on the association of regular physical activity with cognition among individuals with diabetes. Biol. Res. Nurs. 2021 23 3 318 330 10.1177/1099800420966648 33063528
139 Zarza-Rebollo J.A. Molina E. López-Isac E. Pérez-Gutiérrez A.M. Gutiérrez B. Cervilla J.A. Rivera M. Interaction effect between physical activity and the BDNF Val66Met polymorphism on depression in women from the PISMA-ep study. Int. J. Environ. Res. Public Health 2022 19 4 2068 10.3390/ijerph19042068 35206257
140 Mata J. Thompson R.J. Gotlib I.H. BDNF genotype moderates the relation between physical activity and depressive symptoms. Health Psychol. 2010 29 2 130 133 10.1037/a0017261 20230085
141 Takeuchi H. Tomita H. Taki Y. Kikuchi Y. Ono C. Yu Z. Sekiguchi A. Nouchi R. Kotozaki Y. Nakagawa S. Miyauchi C.M. Iizuka K. Yokoyama R. Shinada T. Yamamoto Y. Hanawa S. Araki T. Kunitoki K. Sassa Y. Kawashima R. Effect of the interaction between BDNF Val66Met polymorphism and daily physical activity on mean diffusivity. Brain Imaging Behav. 2020 14 3 806 820 10.1007/s11682-018-0025-8 30617785
142 Caldwell H.A.E. Bryan A.D. Hagger M.S. What keeps a body moving? The brain-derived neurotrophic factor val66met polymorphism and intrinsic motivation to exercise in humans. J. Behav. Med. 2014 37 6 1180 1192 10.1007/s10865-014-9567-4 24805993
143 Ieraci A. Madaio A.I. Mallei A. Lee F.S. Popoli M. Brain-derived neurotrophic factor val66met human polymorphism impairs the beneficial exercise-induced neurobiological changes in mice. Neuropsychopharmacology 2016 41 13 3070 3079 10.1038/npp.2016.120 27388329
144 Lemos J.R. Jr Alves C.R. de Souza S.B.C. Marsiglia J.D.C. Silva M.S.M. Pereira A.C. Teixeira A.L. Vieira E.L.M. Krieger J.E. Negrão C.E. Alves G.B. de Oliveira E.M. Bolani W. Dias R.G. Trombetta I.C. Peripheral vascular reactivity and serum BDNF responses to aerobic training are impaired by the BDNF Val66Met polymorphism. Physiol. Genomics 2016 48 2 116 123 10.1152/physiolgenomics.00086.2015 26603150
145 Watts A. Andrews S.J. Anstey K.J. Sex differences in the impact of BDNF genotype on the longitudinal relationship between physical activity and cognitive performance. Gerontology 2018 64 4 361 372 10.1159/000486369 29402782
146 Helm E.E. Matt K.S. Kirschner K.F. Pohlig R.T. Kohl D. Reisman D.S. The influence of high intensity exercise and the Val66Met polymorphism on circulating BDNF and locomotor learning. Neurobiol. Learn. Mem. 2017 144 77 85 10.1016/j.nlm.2017.06.003 28668279
147 Keyan D. Bryant R.A. Acute exercise-induced enhancement of fear inhibition is moderated by BDNF Val66Met polymorphism. Transl. Psychiatry 2019 9 1 131 10.1038/s41398-019-0464-z 30967530
148 Pitts B.L. Whealin J.M. Harpaz-Rotem I. Duman R.S. Krystal J.H. Southwick S.M. Pietrzak R.H. BDNF Val66Met polymorphism and posttraumatic stress symptoms in U.S. military veterans: Protective effect of physical exercise. Psychoneuroendocrinology 2019 100 198 202 10.1016/j.psyneuen.2018.10.011 30388593
149 Keyan D. Bryant R.A. Role of BDNF val66met polymorphism in modulating exercised-induced emotional memories. Psychoneuroendocrinology 2017 77 150 157 10.1016/j.psyneuen.2016.12.013 28056410
